Markets:

Overview

News

Currencies

International

Treasuries

FibroGen, Inc - Common Stock (NQ:FGEN)

9.710 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about FibroGen, Inc - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

33 Stocks Moving In Friday's Mid-Day Session ↗

July 16, 2021

Gainers TD Holdings, Inc. (NASDAQ: GLG) jumped 49% to $1.21 after the company entered a non-binding letter of intent to acquire Guangdong Jinbochuang Special Purpose Vehicle Co....

Via Benzinga

Analyzing FibroGen's Unusual Options Activity ↗

July 16, 2021

Shares of FibroGen (NASDAQ:FGEN) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $13.83. Sentiment: BEARISH Option...

Via Benzinga

FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fall ↗

July 16, 2021

FibroGen (FGEN) stock is falling hard on Friday after the company received the results of an FDA review for one of its drugs.

Via InvestorPlace

Mid-Morning Market Update: Markets Down; Kansas City Southern Earnings Miss Views ↗

July 16, 2021

Following the market opening Friday, the Dow traded down 0.41% to 34,844.89 while the NASDAQ fell 0.30% to 14,499.54. The S&P also fell, dropping 0.30% to 4,346.93. The U.S....

Via Benzinga

Topics Earnings Stocks

Why FibroGen's Stock Is Getting Hammered Today ↗

July 16, 2021

FibroGen, Inc. (NASDAQ: FGEN) shares are trading lower after an FDA Advisory Committee panel voted against approval of the company's New Drug Application for roxadustat to...

Via Benzinga

FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment ↗

July 16, 2021

A FDA panel voted resoundingly against recommending approval for an anemia treatment from FibroGen, and FGEN stock tanked on Friday.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021 ↗

July 16, 2021

Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE:

Via Benzinga

GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies ↗

July 16, 2021

GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral...

Via Benzinga

10 Biggest Price Target Changes For Friday ↗

July 16, 2021

Credit Suisse raised Cintas Corporation (NASDAQ: CTAS) price target from $350 to $375. Cintas shares rose 1.4% to $374.12 in pre-market trading. Barclays raised the price target...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 16, 2021

Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton...

Via Benzinga

22 Stocks Moving in Friday's Pre-Market Session ↗

July 16, 2021

Gainers Aehr Test Systems (NASDAQ: AEHR) shares rose 25.3% to $3.52 in pre-market trading after the company reported better-than-expected Q4 results and issued strong FY22 sales...

Via Benzinga

FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall? ↗

July 16, 2021

FibroGen, Inc.’s (NASDAQ: FGEN) shares are sinking to their lowest level since late June 2016. FibroGen’s AdCom Snub FibroGen said late Thursday the...

Via Benzinga

What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict ↗

July 14, 2021

FibroGen, Inc. (NASDAQ:FGEN) has a key catalyst Thursday w...

Via Benzinga

Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions ↗

July 13, 2021

Ahead of Thursday's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on the safety of AstraZeneca Plc's...

Via Benzinga

The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗

July 11, 2021

Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback...

Via Benzinga

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs ↗

July 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,...

Via Benzinga

Topics Product Recall

Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates ↗

July 01, 2021

June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive...

Via Benzinga

14 Biotech Stocks To Watch Over The Next 6 Months ↗

June 23, 2021

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme ↗

June 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,...

Via Benzinga

FibroGen In-Licenses Three HiFiBiO Programs For Cancer, Autoimmune Settings ↗

June 17, 2021

FibroGen Inc (NASDAQ: FGEN) and HiFiBiO Therapeutics have entered into a licensing agreement for three programs in the immuno-oncology and autoimmune space....

Via Benzinga

DEADLINE TODAY: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

June 11, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

FIBROGEN CLASS ACTION REMINDER

June 10, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

DEADLINE TOMORROW: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

June 10, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against FibroGen, Inc. and Encourages Investors to Contact the Firm

June 09, 2021

From Bragar Eagel & Squire, P.C.

Via Business Wire

FIBROGEN SHAREHOLDER NOTICE

June 09, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

FGEN Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or June 11, 2021 Deadline in Securities Fraud Class Action Lawsuit

June 09, 2021

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

June 09, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

FRIDAY DEADLINE NOTICE: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

June 09, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

FIBROGEN 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN

June 08, 2021

From Kahn Swick & Foti, LLC

Via Business Wire

FIBROGEN SHAREHOLDER ALERT

June 08, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.